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We synthesized and investigated the effect of formyl peptide receptor 2 (FPR2)-derived pepducins in
human monocytes. The FPR2-based cell-penetrating lipopeptide, ‘‘pepducin” (F2pal-16), stimulated
intracellular calcium increase in humanmonocytes via pertussis toxin (PTX)-sensitive G-protein and
phospholipase C (PLC) activity. From a functional aspect, we showed that F2pal-16 stimulated mono-
cyte chemotaxis. F2pal-16 also stimulated the generation of superoxide anion in human monocytes.
Moreover, F2pal-16 dramatically increased the production of several kinds of pro-inﬂammatory
cytokines (CXCL8, CCL2, IL-1b and TNF-a) in human monocytes via NF-jB activation. Since FPR2
plays an important role in immune responses, F2pal-16 can serve as a useful reagent for the study
of FPR2-mediated immune modulation.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor
which regulates trafﬁcking of leukocytic cells, such as neutrophils,
monocytes, macrophages, and natural killer cells [1–3]. FPR2 has
an important immunologic function, including host defense
against pathogenic infections by stimulating the generation of
reactive oxygen species in human monocytes as well as neutro-
phils [1,2]. In human monocytes, FPR2 is also involved in the
production of some important cytokines, such as CCL2, IL-10, and
TNF-a [4,5]. In human natural killer cells, activation of FPR2 stim-
ulates IFN-c production and cytolytic activity, which suggests that
FPR2 can be regarded as an important target receptor for cancer
therapy [3]. Since human synovial ﬁbroblasts express functional
FPR2, past studies have suggested that FPR2 may be involved in
the pathogenesis of arthritis [6]. Because FPR2 is expressed in sev-
eral important leukocytes and inﬂammatory cells, and the receptorchemical Societies. Published by E
A, serum amyloid A; GPCR, G-
s, mitogen activated protein
PF, high-power ﬁelds; WRW4,
cal Sciences, Sungkyunkwan
82 31 290 7015.
.ac.kr (Y.-S. Bae).is regarded as a possible important target for the treatment of
inﬂammatory diseases, the development of various agents that
modulate FPR2 activity is required.
In terms of ligands for FPR2, many agonists have been identiﬁed,
including host-derived agonists (LL-37, lipoxin A4, and serum amy-
loid A [SAA]), and synthetic peptides (WKYMVm and MMK-1) [7–
11]. Cellular responses induced by these FPR agonists have been
examined in some leukocytic cells, such as neutrophils and mono-
cytes [1,2,7,9]. The activation of FPR2 by one of the strong synthetic
agonists, WKYMVm, induces the activation of NADPH oxidase,
resulting in superoxide anion production [12,13]. However, the
stimulation of human neutrophils or monocytes with WKYMVm
does not induce cytokine production [4]. Another important FPR2
agonist, SAA, stimulates the production of some cytokines, such as
TNF-a, IL-10, and CCL2 [4,5]. However, SAA fails to stimulate super-
oxide production from human monocytes or human neutrophils
[13]. We have demonstrated that the activation of FPR2 by different
ligands induces differential intracellular signaling and cellular re-
sponses, showing a ligand-selective process [4,13]. Although vari-
ous ligands for FPR2 have been reported, many ligands have failed
to stimulate a broad range of activation in phagocytic cells.
The G-protein coupled receptors (GPCR), including FPR2, have
been shown to induce intracellular signaling via the activation of
heterotrimeric G-protein(s) [1,2]. Subsequent mutagenesis studieslsevier B.V. All rights reserved.
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such as the intracellular loop 3 region, are involved in the activa-
tion of GPCR [14]. Based on this background, Kuliopulos and co-
workers developed several membrane-tethering cell permeable
peptides corresponding to the intracellular loop region of PAR as
agonists or antagonist for PAR [15,16]. Pepducin is a membrane-
tethering cell permeable peptide [15]. It has been demonstrated
that pepducins derived from PAR1 or CXCR1 act as agonists or
antagonists for their speciﬁc receptors [15–17]. Even though syn-
thesis of pepducin from GPCR is a novel approach by which to
develop new ligands for the receptor, nothing is known about
FPR2-derived pepducins. In this study, we synthesized a new
FPR2-derived pepducin and tested its effect on human monocyte
activity and the signaling pathways involved in this process.
2. Materials and methods
2.1. Materials
F2pal-16, F2pal-12 and F2pal-7 were synthesized by Anygen
(Gwangju, Korea). Pertussis toxin (PTX), PD98059, SB203580,
SP600125 and SC-514 were from Calbiochem (San Diego, CA).
BAY 11-7082 was purchased from Biomol (Plymouth Meeting,
PA). All the antibodies for phospho-mitogen activated protein ki-
nases (MAPKs) were from Cell Signaling Technology, Inc. (Beverly,
MA). Rabbit anti-human antibodies against FPR2 were purchased
from Gene Tex (San Antonio, TX).
2.2. Isolation of human peripheral blood monocytes
Peripheral blood was collected from healthy adult donors. The do-
nors were conﬁrmed not to have taken anti-inﬂammatory drugs for
at least 4 weeks before sampling. Venous blood was collected and
peripheral blood mononuclear cells were separated on a Histopaque-
1077 gradient. After two washings with Hank’s buffered saline solu-
tion, without Ca2+ and Mg2+, the peripheral blood mononuclear cells
were suspended in RPMI 1640 medium containing 10% FBS and incu-
bated for 60 min at 37 C to allow the monocytes to attach to the cul-
ture dish. The attached monocytes were then collected as described
previously [18]. The isolated cells were used immediately.
2.3. Cell culture
FPR1- or FPR2-expressing RBL-2H3 cells and vector-transfected
RBL-2H3 cells were maintained as previously described [19]. Cells
were maintained at about 1  106 cells/ml under standard incuba-
tor conditions (humidiﬁed atmosphere, 95% air, 5% CO2, 37 C).
2.4. Ca2+ measurement
Intracellular calcium concentration ([Ca2+]i) was determined by
the method of Grynkiewicz using fura-2/AM [20]. Brieﬂy, prepared
cells were incubatedwith 3 lM fura-2/AM at 37 C for 50 min in ser-
um-freeRPMI1640mediumwith continuous stirring.Approximately
2  106 cellswere aliquoted for each assay intoCa2+ free Locke’s solu-
tion (154 mMNaCl, 5.6 mMKCl, 1.2 mMMgCl2, 5 mMHEPES, pH 7.3,
10 mM glucose, and 0.2 mM EGTA). Fluorescence was measured at
500 nm at excitation wavelengths of 340 nm and 380 nm. The ﬂuo-
rescence ratio was then used for calculation of [Ca2+]i..
2.5. Chemotaxis assay
Chemotaxis assays were performed using multiwell chambers
(Neuroprobe Inc., Gaithersburg, MD) [18]. Brieﬂy, prepared human
monocytes were suspended in RPMI 1640 medium at a concentra-tion of 1  106 cells/ml, and 25 ll of the suspension were placed
onto the upper well of a chamber that was separated by a 5 lm
polyhydrocarbon ﬁlter from the peptide-containing lower well.
After incubation for 2 h at 37 C, non-migrated cells were removed
by scraping them out, and cells that migrated across the ﬁlter were
dehydrated, ﬁxed, and stained with hematoxylin (Sigma, St. Louis,
MO). The stained cells in ﬁve randomly chosen high-power ﬁelds
(HPF) (400) in that well were then counted [18].
2.6. Measurement of superoxide anion generation
Superoxide anion generation was determined by measuring
cytochrome c reduction using a microtiter 96-well plate ELISA
reader (Bio-Tek instruments, EL312e, Winooski, VT) as previously
described [12,13]. Human monocytes (2  106 cells in RPMI 1640
medium) were incubated with 5 lM of cytochalasin B at 37 C
for 5 min and then incubated with each peptide in the presence
of 50 lM cytochrome c. Superoxide generation was determined
by measuring light absorption changes at 550 nm over 10 min at
1 min intervals.
2.7. Cytokine assay
Cytokine measurements were performed as previously de-
scribed [4,5]. Human monocytes (3  105 cells/0.3 ml) were placed
in RPMI 1640 medium containing 1% FBS in 24-well plates and
kept in a 5% CO2 incubator at 37 C. After stimulation, the cell-free
supernatants were collected, centrifuged, and measured for CCL2
by enzyme-linked immunosorbent assay (ELISA) (BD Biosciences
Pharmingen, San Diego, CA) according to the manufacturer’s
instruction.
2.8. Measurement of NF-jB activity
Nuclear extracts were prepared from monocytes with the Nu-
clear Extraction kit (Panomics, Inc. Fremont, CA) for use with a
transcription factor assay kit. Brieﬂy, monocytes (1  106 cells in
RPMI 1640 medium) were incubated with F2pal-16, SAA, or
MMK-1 for 30 min. Cells were harvested and washed twice with
PBS, and resuspended in 250 ll of lysis buffer (Buffer A). All the
cells were incubated on ice for 10 min and then centrifuged at
14 000g for 3 min at 4 C. The supernatants were discarded and
the pellets kept on ice. Pellets were resuspended in 150 ll of
extraction buffer (Buffer B) and incubated for 2 h on ice. Nuclear
debris was removed by centrifugation (14 000g for 5 min at
4 C), and the nuclear protein extract was used for NF-jB p65 nu-
clear transcription factor ELISA kit (Panomics, Inc. Fremont, CA)
according to the manufacturer’s instructions.
2.9. Data analysis
The results are expressed as mean ± S.E.M. of the number of
determinations indicated. Statistical signiﬁcance of differences
was determined by student t-test and statistical signiﬁcance was
considered signiﬁcant at P < 0.05.
3. Results
3.1. FPR2-pepducin stimulates an increase in intracellular calcium in
human monocytes
It has been demonstrated that activation of FPR2 elicits an in-
crease in intracellular calcium in human monocytes [21]. In the
current study, we synthesized human FPR2 intracellular loop 3-
based pepducins in a search for an intracellular agonist of FPR2
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its complete reverse sequence palmitoylated peptide for control
of active pepducin (Fig. 1A). We examined the effects of three dif-
ferent FPR2 pepducins on the increase in intracellular calcium in
human monocytes. Among three FPR2 pepducins tested, F2pal-
16, but not F2pal-7 or F2pal-12, stimulated an increase in intracel-
lular calcium in human monocytes (Fig. 1B). F2pal-16 stimulated
an increase in calcium in monocytes in a concentration-dependent
manner, showing maximal activity at approximately 5 lM
(Fig. 1C). We also tested the effect of peptide corresponding to
F2pal-16 and scrambled pepducin of F2pal-16, neither of which
had an effect on calcium signaling in human monocytes (Fig. 1B).
The results strongly indicate that F2pal-16 speciﬁcally stimulates
calcium signaling in human monocytes.
3.2. F2pal-16-stimulated calcium increase is mediated by FPR2
Because F2pal-16 was synthesized based on the FPR2 intracel-
lular loop 3 sequence, we reasoned that F2pal-16 directly activates
FPR2 in human monocytes. To conﬁrm this, we examined whether
F2pal-16 required the presence of FPR2 to activate signaling. We
tested the effect of F2pal-16 on Ca2+ mobilization in FPR1-, or
FPR2-expressing RBL-2H3 cells with vector-transfected cells as
control. As shown in Fig. 2A, F2pal-16 stimulated Ca2+ release in1 min
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Fig. 1. F2pal-16 stimulates intracellular calcium increase in primary human
monocytes. The sequences of FPR2-based pepducins (A). Freshly isolated human
peripheral blood monocytes were loaded with Fura-2/AM. Fura-2 loaded cells were
stimulated with 10 lM of each molecule (F2pal-7, F2pal-12, F2pal-16, pep-16, or
scPal-16). The changes in 340/380 nm were monitored. The results are represen-
tative of three independent experiments (B). Fura-2 loaded cells were stimulated
with various concentrations of F2pal-16 (0, 0.01, 0.1, 0.5, 1, 5, or 10 lM), and
intracellular [Ca2+]i was measured. The results are presented as the means ± S.E. of
three independent experiments. (C). *, P < 0.05, compared with the value obtained
from the control (scF2pal-16 treated).FPR2-expressing RBL-2H3 cells, but there was no effect in FPR1-
expressing or vector-transfected cells. As a control, a well-known
FPR1 agonist (WKYMVm) [22] strongly stimulated calcium in-
crease in FPR1-expressing RBL-2H3 cells (Fig. 2A). This ﬁnding
strongly indicates that F2pal-16 speciﬁcally stimulates FPR2, elicit-
ing an increase in calcium. We also tested the effect of F2pal-16 on
the FPR2-speciﬁc agonist (MMK-1)-induced calcium signaling, and
vice versa. MMK-1 could not further increase intracellular calcium
levels over those attained by treatment with F2pa1-16, and vice
versa (Fig. 2B). Next, we tested the effect of FPR2 antagonist
(WRWWWW, WRW4) [19] on the F2pal-16-stimulated increase
in intracellular calcium in FPR2-expressing RBL-2H3 cells.
Although WRW4 speciﬁcally inhibited the MMK-1-stimulated in-
crease in calcium in FPR2-expressing RBL-2H3 cells, the F2pal-
16-stimulated increase in calcium was not affected byWRW4 (data
not shown).
It has been demonstrated that FPR2-stimulated signaling is
mediated by PTX-sensitive G-protein [23]. We tested the role of
PTX-sensitive G-protein in F2pal-16-stimulated calcium signaling.
The F2pal-16-stimulated increase in calcium was completely
inhibited by PTX (Fig. 2C). Stimulation of calcium signaling by
MMK-1, a well-known FPR2 agonist, was also completely inhibitedVector
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Fig. 2. F2pPal-16-induced intracellular calcium increase is mediated by FPR2. Fura-
2/AM loaded FPR1- or FPR2-expressing RBL2H3 cells, or RBL2H3 cells transfected
with empty vector, were stimulated with 5 lM F2pal-16 or 100 nM WKYMVm (A).
FPR2-expressing RBL-2H3 cells were sequentially stimulated with 10 lM F2pal-16
or 1 lM MMK-1 as indicated in the ﬁgure (B). FPR2-expressing RBL2H3 cells were
incubated with vehicle or 100 ng/ml PTX for 24 h, and then the cells were loaded
with Fura-2/AM. Fura-2/AM-loaded cells were treated with F2pal-16 (5 lM) or
MMK-1 (1 lM) (C) and changes in 340/380 nm were monitored. The results are
representative of three independent experiments (A–C).
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lates calcium signaling via PTX-sensitive G-protein(s).
Many GPCRs, including FPR2, induce calcium signaling via the
activation of phospholipase C (PLC) [24]. To determine whether
F2pal-16 also acts via PLC, we pretreated FPR2-expressing
RBL-2H3 cells with a speciﬁc PLC inhibitor (U-73122) prior to the
addition of F2pal-16. F2pal-16-induced calcium signaling wasM
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Fig. 3. F2pal-16 stimulates monocyte migration through a PTX-sensitive G-protein
dependent signaling pathway. For all experiments, freshly isolated human periph-
eral blood monocytes (1  106 cells/ml of serum-free RPMI 1640 medium) were
added to the upper well of a 96-well chemotaxis chamber and assessed for
migration across a membrane with a 5 lm pore size after incubation at 37 C for
2 h. The number of cells which migrated across the membrane was determined by
counting the cells in ﬁve microscope high-power ﬁelds (400; HPF). Various
concentrations of F2pal-16 were used in the lower chamber for the chemotaxis
assay (A). The cells were incubated in the presence or absence of 100 ng/ml PTX for
24 h before the chemotaxis assay. Vehicle (DMSO), 5 lM F2pal-16, 2 lM SAA, and
1 lM MMK-1 were added to the lower chamber for the chemotaxis assay (B).
Human monocytes were incubated in the presence or absence of 10 lM WRW4 for
30 min, and then subjected to the chemotaxis assay. Vehicle (DMSO), 5 lM F2pal-
16, 2 lM SAA, and 1 lM MMK-1 were used added to the lower chamber (C). The
results are presented as the means ± S.E. of three independent experiments (A–C).
*P < 0.05, compared with the value obtained from the control (scF2pal-16 treated)
(A); #P < 0.05, signiﬁcantly different from the control (–PTX or –WRW4) (B and C).completely inhibited by U-73122, indicating that F2pal-16 stimu-
lates calcium signaling by activation of PLC (data not shown). Stim-
ulation by the FPR2 agonist MMK-1 was also completely inhibited
by U-73122 in FPR2-expressing RBL-2H3 cells (data not shown).
3.3. F2pal-16 stimulates chemotactic migration of human monocytes
FPR2 is well-characterized as a classical chemoattractant recep-
tor [1]. Stimulation of FPR2 by its selective agonist induces chemo-
tactic migration of human monocytes [1,2]. In this study, we
investigated the effect of F2pal-16 on monocyte chemotaxis. Addi-
tion of various concentrations of F2pal-16 induced chemotactic
migration of monocytes in a concentration-dependent manner
(Fig. 3A). Maximal activity was shown at approximately 5 lM. Pre-
incubation of human monocytes with PTX prior to the chemotaxis
assay using F2pal-16 caused complete inhibition of F2pal-16-in-
duced chemotactic migration (Fig. 3B), demonstrating the role of
PTX-sensitive G-protein(s) in this process. We also tested the effect
of WRW4 on the FPR2 agonist-induced monocyte chemotaxis. Pre-
incubation of human monocytes with 10 lM WRW4 prior to the
chemotaxis assay caused dramatic inhibition of monocyte chemo-
taxis induced by SAA or MMK-1 (Fig. 3C). However, F2pal-16-in-
duced monocyte chemotaxis was not affected by WRW4 (Fig. 3C).
3.4. F2pal-16. stimulates superoxide anion production in human
monocytes
One of the important roles of monocytes in innate immune re-
sponses is the production of reactive oxygen species, such as
superoxide anion [25]. We determined the effects of F2pal-16 on0 0.01 0.1 1 5 10
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Fig. 5. F2pal-16 stimulates the production of pro-inﬂammatory cytokines from human monocytes. Freshly isolated human peripheral blood monocytes were treated with
5 lM F2pal-16 for various times (0, 1, 3, 6, 12, or 24 h) (A and B); with various concentrations of F2pal-16 (0.01, 0.1, 1, 5, and 10 lM) for 12 h (C); with vehicle or 100 ng/ml of
PTX for 24 h before treatment with vehicle, F2pal-16 (5 lM), SAA (2 lM), or MMK-1 (1 lM) (D); or incubated in the presence or absence of 10 lM WRW4 for 30 min before
treatment with vehicle, F2pal-16 (5 lM) or SAA (2 lM) (E). Secreted CXCL8 (A) and CCL2 (B–E) levels were determined by ELISA. The results are presented as the means ± S.E.
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tion assay. F2pal-16 stimulated superoxide anion production in a
concentration-dependent manner, showing maximal activity at
5 lM (Fig. 4A). The superoxide anion-producing activity of F2pal-
16 was compared with that of two other FPR2 agonists, SAA and
MMK-1. Stimulation of human monocytes with MMK-1 (1 lM) en-
hanced superoxide anion production (Fig. 4B). The MMK-1-in-
duced superoxide anion production was about twofold more
potent than that observed with F2pal-16. However, stimulation
of human monocytes with SAA (2 lM) failed to enhance superox-
ide anion production (Fig. 4B).
3.5. F2pal-16 stimulates production of several inﬂammatory cytokines
in human monocytes
The effect of F2pal-16 on the production of several cytokines
was investigated in human monocytes. When the cells were stim-ulated with 5 lM F2pal-16, F2pal-16 induced IL-8 production was
assayed at various times, and showed maximal activity within 12 h
of stimulation (Fig. 5A). F2pal-16 also stimulated the production of
TNF-a, IL-1b, and CCL2 in human monocytes (Fig. 5B and data not
shown). F2pal-16-induced TNF-a production was maximal 6 h
after stimulation. IL-1b and CCL2 production by F2pal-16 was max-
imal approximately 12 h after stimulation (Fig. 5B and data not
shown). Stimulation of human monocytes with various concentra-
tions of F2pal-16 induced CCL2 production in a concentration-
dependent manner (Fig. 5C).
We also compared the effect of F2pal-16, MMK-1, or SAA on the
production of CCL2 in human monocytes. Stimulation of human
monocytes with F2pal-16 (5 lM), or SAA (2 lM) for 24 h elicited
CCL2 production (Fig. 5D). However, MMK-1 (5 lM) failed to stim-
ulate CCL2 production from the cells (Fig. 5D). We then tested the
role of PTX-sensitive G-protein on the agonist-stimulated CCL2
production from human monocytes. Preincubation of human
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Fig. 6. F2pal-16-stimulated CCL2 production is mediated by NF-jB activity. Human
monocytes were stimulated with vehicle F2pal-16 (5 lM), SAA (2 lM), or MMK-1
(5 lM) for 30 min. Nuclear protein was extracted and NF-jB activity was measured
using a NF-jB activity measuring kit (A). Human monocytes were pre-incubated
with several concentrations of BAY 11-7082 or SC-514 (0, 1, 5, 10, and 20 lM) at
37 C for 1 h, followed by stimulation with 5 lM of F2pal-16 for 12 h (B). Secreted
CCL2 levels were determined by ELISA (B). The results are presented as the
means ± S.E. of three independent experiments. *P < 0.05, compared with the value
obtained from the control (vehicle treated); #P < 0.05, signiﬁcantly different from
the control (F2pal-16 only treated) (B).
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ited CCL2 production by these two agonists (Fig. 5D), indicating
that F2pal-16 or SAA-induced CCL2 production is mediated by
PTX-sensitive G-protein(s). Preincubation of human monocytes
with 10 lM WRW4 prior to the addition of SAA or F2pa1-16 led
to dramatic inhibition of CCL2 production by SAA (Fig. 5E), whereas
F2pal-16-stimulated CCL2 production was not inhibited by WRW4
(Fig. 5E).
3.6. F2pal-16 stimulates NF-jB activity, resulting in CCL2 production
in human monocytes
Past studies have demonstrated that the expression of the CCL2
gene requires the activation of NF-jB [26,27]. We also tested the
effect of F2pal-16 on NF-jB activity in human monocytes using
an ELISA kit to detect activated NF-jB. The NF-jB activity was en-
hanced after exposing monocytes to F2pal-16 for 30 min (Fig. 6A).
We further investigated the role of NF-jB on F2pal-16-induced
CCL2 production by using two NF-jB inhibitors (BAY 11-7082
and SC-514). CCL2 production by F2pal-16 was almost completely
inhibited by two inhibitors (Fig. 6B). The results indicate that NF-
jB is required for F2pal-16-induced CCL2 production in human
monocytes. Another FPR2 agonist, SAA, but not MMK-1, stimulated
NF-jB activity in human monocytes (Fig. 6A). The result was cor-
related with the data that SAA, but not MMK-1, stimulated produc-
tion of pro-inﬂammatory cytokines such as CCL2 from human
monocytes.4. Discussion
Palmitoylated peptide sequences of some GPCRs are known to
act as ligands or modulators of GPCRs [16,17]. In this study we
developed a novel FPR2 agonist, F2pal-16, which stimulates
FPR2-induced G-protein activation. The pepducin stimulated a
broad range of cellular responses in human monocytes, including
superoxide anion production, chemotactic migration, and cytokine
production. We demonstrated that one palmitoylated peptide
(F2pal-16) can act a novel agonist for FPR2.
Characterization of F2pal-16 as an agonist for FPR2 revealed
that F2pal-16 stimulates a broad range of cellular responses,
including superoxide anion production, chemotactic migration,
and cytokine production. Some agonists for FPR2 stimulated a lim-
ited range of cellular responses. For example, WKYMVm potently
stimulates chemotactic migration and superoxide anion produc-
tion, but fails to stimulate cytokine (CXCL8 and CCL2) production
in human neutrophils [13,28]. SAA strongly stimulates chemotactic
migration and cytokine production, but does not stimulate super-
oxide anion production in human neutrophils [13]. In contrast,
we have demonstrated that F2pal-16 stimulates all tested cellular
responses (chemotactic migration, superoxide anion production,
and cytokine production) in human monocytes. WKYMVm and
SAA are peptide ligands that act on the receptor without mem-
brane-tethering, whereas F2pal-16 stimulates FPR2 after mem-
brane-tethering. It has been shown in other studies that
pepducins act on the juxtaposed region of GPCR and G-protein(s)
[16,17,29]. We suggest that F2pal-16 stimulates a broad range of
cellular responses because it can act on FPR2 with a unique mech-
anism of action.
In terms of the site of action of F2pal-16 on FPR2, it may bind to
a site distinct from that of extracellular ligands. In this study we
examined the effect of WRW4 (an FPR2 antagonist) on F2pal-16-in-
duced signaling. Pretreatment of WRW4 prior to F2pal-16 treat-
ment did not block F2pal-16-induced calcium signaling (data not
shown). However, WRW4 pretreatment completely blocked cal-
cium signaling induced by another FPR2 agonist, MMK-1 (data
not shown). Previous work has demonstrated that pepducin, which
is synthesized from the intracellular loop of GPCR, acts intracellu-
larly by regulating the coupling of heterotrimeric G-protein and
target GPCR [16,17]. In our study, we synthesized a pepducin pep-
tide based on the intracellular loop 3 region of FPR2, which is ex-
pected to act on an intracellular target, but not on the cell
surface. Keeping in mind that WRW4 is an antagonist which acts
on the cell surface receptor in the extracellular milieu, it makes
sense that F2pal-16-induced calcium signaling was not inhibited
by WRW4. As shown in Figs. 3 and 5, WRW4 only blocked mono-
cyte chemotaxis or CCL2 production induced by SAA or MMK-1,
but not that induced by F2pal-16. These results suggest that
F2pal-16 has a different binding site from that of WRW4 on FPR2.
Past study already clearly demonstrated that palmitoylated pep-
tides act on the intracellular region of speciﬁc GPCRs such as
PAR1 [30]. Taking together the past study and our data, we can
suggest that our F2pal-16 also acts on the intracellular region of
FPR2. In terms of receptor speciﬁcity of F2pal-16 in the FPR family,
we clearly demonstrated that F2pal-16 stimulates FPR2 but not
FPR1 (Fig. 2). Since human primary monocytes express all 3 FPRs
(FPR1, FPR2 and FPR3), at this point we could not clearly rule out
an involvement of FPR3 on the F2pal-16-induced responses in hu-
man monocytes.
Several previous reports have demonstrated that NF-jB is re-
quired for the induction of CCL2 in some cell types [26,27]. We
demonstrated that F2pal-16 stimulates NF-jB (Fig. 6A). Regarding
the role of NF-jB on F2pal-16-induced CCL2 induction, we ob-
served that BAY 11-7082 completely inhibited F2pal-16-induced
CCL2 production from human monocytes (Fig. 6B), suggesting that
4108 H.Y. Lee et al. / FEBS Letters 584 (2010) 4102–4108the NF-jB pathway is required for the induction of CCL2 by F2pal-
16 in monocytes. Taken together, the results suggest that NF-jB
signaling is a prerequisite for the proper induction of CCL2 by
F2pal-16 in monocytes. Keeping in mind that F2pal-16 permeabi-
lizes and stimulates FPR2, thus eliciting G-protein activation, it is
reasonable to suggest that F2pal-16 induces the activation of a
broad range of signaling down-stream of FPR2, resulting in the
activation of the NF-jB pathway.
In conclusion, we have developed a novel FPR2-speciﬁc mem-
brane-tethering cell permeable peptide, F2pal-16. Since F2pal-16
stimulated a broad range of FPR2 down-stream signaling resulting
in superoxide anion production and cytokine production, this mol-
ecule can be regarded as an important ligand for the study of the
mechanism of activation and immunologic role of FPR2.
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